Publications by authors named "Victoria Lock"

Claim this Profile
A
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Lucas Moreno, Lynley V Marshall, Andrew D J Pearson, Bruce Morland, Martin Elliott, Victoria Lock

Clin Cancer Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
James Foran, Farhad Ravandi, William Wierda, Guillermo Garcia-Manero, Srdan Verstovsek, Victoria Lock

Clin Lymphoma Myeloma Leuk· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of human soluble adenylate cyclase reveals a distinct, highly flexible allosteric bicarbonate binding pocket.
Susanne M Saalau-Bethell, Valerio Berdini, Anne Cleasby, Miles Congreve, Joseph E Coyle, Victoria Lock

ChemMedChem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, Simon P Heaton, Mike I Walton, Victoria Lock

Mol Cancer Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Matthew S Squires, Laurence Cooke, Victoria Lock, Wenqing Qi, E Jonathan Lewis

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis